Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei

In 2014, a published report of the high-throughput screen of>42,000 kinase inhibitors from GlaxoSmithKline against T. brucei identified 797 potent and selective hits. From this rich data set, we selected NEU-0001101 (1) for hit-to-lead optimization. Through our preliminary compound synthesis and SAR studies, we have confirmed the previously reported activity of 1 in a T. brucei cell proliferation assay and have identified alternative groups to replace the pyridyl ring in 1. Pyrazole 24 achieves improvements in both potency and lipophilicity relative to 1, while also showing good in vitro metabolic stability. The SAR developed on 24 provides new directions for further optimization of this novel scaffold for anti-trypanosomal drug discovery.Boettcher Foundation's Webb-Waring Biomedical Research Program; Boettcher Collaboration Grant; Research Corporation Cottrell College Science Award; National Institute of Allergy and Infectious Diseases (US):R01AI114685; Ministerio de Economia, Industria y Competitividad (España) SAF2015-71444-P; SAF2015-68042-R; SAF2016-79957-R; Junta de Andalucia CTS-7282; Subdireccion General de Redes y Centros de Investigacion Cooperativa (RICET) RD16/0027/0019, DG-P RD16/0027/0014; NSF-MRI CHE-1429567Peer reviewe